Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results
Date:5/7/2013

NEW YORK, May 7, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the first quarter ended March 31, 2013.

At March 31, 2013, the Company had cash and cash equivalents of $87.3 million, as compared to $14.7 million at December 31, 2012.  On January 30, 2013, the Company completed an underwritten public offering of common stock, which provided proceeds to the Company of approximately $74.8 million, net of underwriting discounts and offering expenses of approximately $5.6 million. Also in January 2013, the Company received a $7.0 million milestone payment from its Japanese partner for Zerenex (ferric citrate), Japan Tobacco Inc. ("JT") and Torii Pharmaceutical Co., Ltd. ("Torii"), related to JT's January 2013 filing of a New Drug Application ("NDA") with the Japanese Ministry of Health, Labour and Welfare for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease ("CKD").

The net loss for the first quarter ended March 31, 2013 was $2.1 million, or $0.03 per share, compared to a net loss of $9.1 million, or $0.13 per share, for the comparable quarter in 2012, representing a decrease in net loss of $7.0 million.  In January 2013, the Company recorded license revenue of $7.0 million for the milestone payment received from its Japanese partner for Zerenex, JT & Torii, as discussed above. The net loss for the first quarter ended March 31, 2013, included $0.6 million of non-cash compensation expense related to equity incentive grants.

Commenting on the quarter, Ron Bentsur <
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
4. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
5. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
6. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
8. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 ... healthcare funding changes brought about by the ... both reimbursement and prescribing of pharmaceutical therapies. ... (MCOs) cover beneficiaries through new regulations and ... is occurring in the health exchanges—state-based marketplaces ...
(Date:7/31/2014)... Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval inspection ... The inspection, carried out by the FDA Consumer Safety Officer, ... planned, started on 21 st July and concluded on ... be compliant with the principles and guidelines of Good Manufacturing ...
(Date:7/31/2014)...  Zacks.com announces the list of stocks featured in the ... the latest news and events impacting stocks and the financial ... BIIB - Free Report ), Gilead (Nasdaq: GILD ... Free Report ), AbbVie (NYSE: ABBV - Free Report ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... SHAWNEE, Kan., June 17, 2011 Bayer HealthCare LLC ... of the lawsuit between Bayer and Farnam Companies Inc. ... tick control products.  As part of the settlement, Farnam ... Farnam,s print and online advertising campaign included claims that ...
... 17, 2011 NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank, CEO, received the ... 2011 New England Award in the Medical Devices category. ... extraordinary success in such areas as innovation, financial performance ...
Cached Medicine Technology:Bayer Announces Farnam Companies' Agreement to Halt Disputed Bio Spot® Ads 2NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 2NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 3NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 4
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
(Date:7/31/2014)... NV (PRWEB) July 31, 2014 Niche Profit ... Adam Short that is designed to provide a blueprint for ... the attention of Shane Michaels, prompting an investigative review. ... , “What really speaks volumes about the success of the ... and strategies included in it have stayed effective even through ...
(Date:7/31/2014)... Vegas, NV (PRWEB) July 31, 2014 Hook Your ... way to get ex’s to feel emotionally hungry for their partner, ... a second chance. This little trick has been taught to ... , After a quick Hook Your Ex review , Shane ... who is suffering pain from a breakup a second chance at ...
(Date:7/31/2014)... 31, 2014 Cosmetic Town has introduced ... and doctors. Doctors will be able to verify their ... reviews , which guarantees their authenticity. This will ... site to receive information that has been verified to ... system allows Cosmetic Town to filter out fake patients ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 ... Pioneer Millworks’ reclaimed wood to create a unique ... Their newest location features reclaimed barn siding ... with custom selected mixed softwoods flowing throughout the ... by Pioneer Millworks’ sister company New Energy ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2
... Dynamic Packaging and Graphical User Interface, BOCA ... AGYS ), a leading provider of innovative IT ... version of the Lodging Management System(R) (LMS) property,management ... in Austin, Texas,June 16-19., LMS v8.0 ...
... WASHINGTON, June 17 Federally Employed Women,(FEW) salutes ... the,"Federal Employees Paid Parental Leave Act of 2008" ... John Warner (R-VA), Hillary Rodham Clinton (D-NY), John,Kerry ... Richard,Durbin (D-IL) for co-sponsoring this important bill. "We ...
... Gene mutations that make cells cancerous can sometimes also ... by cancer researchers at Ohio State University shows that a ... disease more susceptible to high doses of a particular anticancer ... B clinical cooperative group study led by Dr. Clara D. ...
... PHILADELPHIA Researchers from the University of Pennsylvania School ... pathway important in stem cell and developmental biology leads ... knowledge could help develop therapies for lung-tissue repair after ... last week in advance of print publication in ...
... to the public, agency says , , TUESDAY, June 17 (HealthDay ... letters warning more than two dozen companies to stop selling ... The agency is also cautioning consumers not to buy or ... and creams, and are sold under various names on the ...
... is only a minor ... problem,- 57% are unaware that diaper rash can be accompanied ... and boys, - 59% responded "no" or were unsure when asked if there was ... between diaper rash and antibiotics, PRINCETON, N.J., June 17 ...
Cached Medicine News:Health News:Agilysys Announces Latest Version of Lodging Management System(R) (LMS) 2Health News:FEW Salutes Senator for Introducing Paid Parental Leave Bill 2Health News:Gene mutation improves leukemia drug's effect 2Health News:Penn researchers find key developmental pathway activates lung stem cells 2Health News:FDA Warns Companies to Stop Selling Fake Cancer Cures 2Health News:FDA Warns Companies to Stop Selling Fake Cancer Cures 3Health News:Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment 2Health News:Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment 3Health News:Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment 4
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
Enzyme Immunoassay for the quantitative ( qualitative 0020, on request) determination of IgG Class antibodies to Rubella virus....
Donor Screen & Confirmation Kit...
... This SIGNET anti-PSA antibody gives ... all cases of benign hyperplasia. In ... intense staining and 34% give definite ... only a minority of cells; this ...
Medicine Products: